---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-041312"
form_type: "8-K"
ticker: "TRVI"
cik: "0001563880"
company_name: "Trevi Therapeutics, Inc."
filed_at: "2023-08-10T23:59:59+00:00"
generated_at: "2026-06-11T17:30:24.088991+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Trevi Therapeutics Q2 net loss $7.1M; cash $94.2M; three chronic cough trials on track for H2 2023

## Summary
- Net loss of $7.1M in Q2 2023 vs. $8.1M in Q2 2022; R&D expenses rose to $5.8M.
- Cash, cash equivalents and marketable securities $94.2M at June 30, 2023.
- Plans to initiate three chronic cough trials (Phase 2b IPF, Phase 1b IPF, Phase 2a RCC) in H2 2023 remain on track.
- Human Abuse Potential study delayed due to IV butorphanol shortage from supplier tornado damage.
- Phase 2 CANAL trial data published in NEJM Evidence; term loan of $6.5M repaid in May 2023.

## SEC filing metadata
- accession: 0000950170-23-041312
- form_type: 8-K
- ticker: TRVI
- cik: 0001563880
- company_name: Trevi Therapeutics, Inc.
- filed_at: 2023-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1563880/000095017023041312/0000950170-23-041312-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1563880/000095017023041312/trvi-20230810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-041312
- JSON: https://secwatch.observer/filing/0000950170-23-041312.json
- Plain text: https://secwatch.observer/filing/0000950170-23-041312.txt

## Key facts
- Earnings Releases
  Trevi Therapeutics, Inc. reported the quarter ended June 30, 2023 results: net income Net loss: For the second quarter of 2023, the Company reported a net loss of $7.1 million, compared to a net loss of $8..
  - Period: the quarter ended June 30, 2023
  - Net income: Net loss: For the second quarter of 2023, the Company reported a net loss of $7.1 million, compared to a net loss of $8.
  - Result: reported results
  source text: On August 10, 2023, Trevi Therapeutics, Inc., a Delaware corporation (the "Company") announced its financial results for the quarter ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1563880/000095017023041312/0000950170-23-041312-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.